March 26, 2020: Lopinavir/ritonavir falls short against COVID-19; impact of PrEP scale-up on HIV diagnoses; long-term cost-effectiveness of various HIV interventions; disparities in virologic suppression among young people.
New data shows the drug is not more likely to cause birth defects.
Feb. 6, 2020: HIV medication costs outpace inflation; HIV's role in attenuating childhood vaccinations; the challenges of researching effects of medications during pregnancy; the need for localized HIV interventions in the U.S.
Jan. 30, 2020: Polypharmacy vs. drug interaction risk among people living with HIV as they age; cost-effectiveness of ibalizumab; PrEP persistence on Medicaid vs. private health coverage.
Oral Arguments in Antitrust Case Against HIV Drug Companies Began Last Week. Plaintiff Peter Staley Explains the Case
The case could change the way pharma companies make agreements to keep generic versions of single-tablet pills at bay.
Will a given development in HIV make a difference in the clinic? Will it change practice? Is this something I should know if I take care of people living with HIV? The answer to each of these must be yes for the story to make the list.
The findings will help providers manage patients who have known or potential resistance to NRTIs, but who we want to place on a simplified antiretroviral regimen.
Oct. 31, 2019: HCV treatment efficacy regardless of injection drug use; chronic pain, marijuana, and prescription opoids; the most urgent HIV training priorities; neuro effects of switching from Atripla to Complera.
What Needs to Happen Before California Pharmacies Can Sell PrEP and PEP Without an Initial Prescription
Pharmacists will increasingly play a role in pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) access in California.
Amidst uncertainty regarding the safety of some integrase inhibitors during pregnancy, a study shows that an older integrase inhibitor may be a good option for those with HIV who intend to give birth.